Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

uniQure Gets Its Groove On: An Interview With CEO Jörn Aldag

Executive Summary

UniQure made history in 2012 for winning approval in the EU for the first gene therapy accepted by regulators in a major market. CEO Jörn Aldag shares his views on uniQure's ambitious expansion plans.

You may also be interested in...



Third Rock Takes On Parkinson's, Gene Therapy's Next Frontier

As gene therapy moves closer toward becoming an established therapeutic mode, developers have focused mainly on ophthalmology and monogenic rare diseases, but improvements in vector technology are pointing the field toward targets in the central nervous system. The latest entrant is Voyager Therapeutics Inc., which launched in February with a $45 million Series A commitment from Third Rock Ventures and a lead program in Parkinson's disease.

uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy

uniQure has licensed commercial rights covering Europe and select emerging markets to Italy’s Chiesi for first-to-market gene therapy Glybera and a developmental hemophilia B product. The Dutch biopharma is writing the book on pricing and commercialization, regulatory approval, and market access strategy for gene therapy.

Gene Therapy Firm AMT Forced To Go Private, Backed By Forbion

Amsterdam Molecular Therapeutics plans to be acquired by a newly formed private company, uniQure, and to delist from Euronext.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel